The way forward in treating pancreatic cancer

Buanes, T. , Maurel, J. , Liauw, W. , Hebbar, M. and Nemunaitis, J. ( 2009) A randomized phase III study of gemcitabine (G) versus GV1001 in sequential combination with G in patients with unresectable and metastatic pancreatic cancer. J Clin Oncol 27: 4601 [Abstract].

Casper, E. , Green, M. , Kelsen, D. , Heelan, R. , Brown, T. , Flombaum, C. et al. (1994) Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12: 29-34.

Chu, G. , Kimmelman, A. , Hezel, A. and DePinho, R. ( 2007) Stromal biology of pancreatic cancer. J Cell Biochem 101: 887-907.

Davidson, J. , Ma, L. , Flagella, M. , Geeganage, S. , Gelbert, L. and Slapak, C. ( 2004) An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 64: 3761-3766.

Farrell, J. , Garcia, M. , Lai, R. , Ammar, A. , Regine, W. , Abrams, R. et al. (2007) Human Ent1 is predictive of response in patients with pancreatic cancer treated with gemcitabine: results from the RTOG 9704 prospective randomized trial. Pancreas 35: 401-402.

Galmarini, C. , Myhren, F. and Sandvold, M. (2009) CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines. Br J Haematol 144: 273-275.

Greer, J. , Whitcomb, D. and Brand, R. ( 2007) Genetic predisposition to pancreatic cancer: a brief review . Am J Gastroenterol 102: 2564-2569.

Harris, L. , Fritsche, H. , Mennel, R. , Norton, L. , Ravdin, P. , Taube, S. et al. (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25: 5287-5312.

Itoi, T. , Sofuni, A. , Fukushima, N. , Itokawa, F. , Tsuchiya, T. , Kurihara, T. et al. (2007) Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas . J Gastroenterol 42: 389-394.

Javle, M. , Okazaki, T. , Evans, D. , Wolff, R. , Abbruzzese, J. and Li, D. ( 2008) Polymorphisms of genes involved in gemcitabine metabolism correlate with prognosis in patients receiving neoadjuvant therapy for pancreatic cancer. J Clin Oncol 26: 4501 [Abstract].

Jones, S. , Zhang, X. , Parsons, D. , Lin, J. , Leary, R. , Angenendt, P. et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-1806.

Kindler, H.L. ( 2007) Pancreatic cancer: an update. Curr Oncol Rep 9: 170-176.

Kindler, H. , Garbo, L. , Stephenson, J. , Wiezorek, J. , Sabin, T. , Hsu, M. et al. (2009) A phase Ib study to evaluate the safety and efficacy of AMG 655 in combination with gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (PC). J Clin Oncol 27: 4501 [Abstract].

Lievre, A. , Bachet, J. , Boige, V. , Cayre, A. , Le Corre, D. , Buc, E. et al. (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab . J Clin Oncol 26: 374-379.

Mackenzie, M. , Saltman, D. , Hirte, H. , Low, J. , Johnson, C. , Pond, G. et al. (2007) A phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium. Invest New Drugs 25: 553-558.

Mackey, J. , Mani, R. , Selner, M. , Mowles, D. , Young, J. , Belt, J. et al. (1998) Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines . Cancer Res 58: 4349-4357.

Maitra, A. , Fukushima, N. , Takaori, K. and Hruban, R. ( 2005) Precursors to invasive pancreatic cancer. Adv Anat Pathol 12: 81-91.

Moore, M. , Goldstein, D. , Hamm, J. , Figer, A. , Hecht, J. , Gallinger, S. et al. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966.

Moore, M. , Hamm, J. , Dancey, J. , Eisenberg, P. , Dagenais, M. , Fields, A. et al. (2003) Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21: 3296-3302.

Philip, P. , Benedetti, J. , Fenoglio-Preiser, C. , Zalupski, M. , Lenz, H. , O’Reilly, E. et al. (2007) Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. J Clin Oncol 25: LBA4509 [Abstract].

Poplin, E. , Feng, Y. , Berlin, J. , Rothenberg, M. , Hochster, H. , Mitchell, E. et al. (2009) Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27: 3778-3785.

Richards, D.A. ( 2005) Chemotherapeutic gemcitabine doublets in pancreatic carcinoma . Semin Oncol 32(4 Suppl 6): S9-S13.

Rocco, J. and Sidransky, D. ( 2001) p16(MTS-1/ CDKN2/INK4a) in cancer progression. Exp Cell Res 264: 42-55.

Surveillance Epidemiology and End Results (SEER) (2009) Estimated new cancer rates and deaths for 2009. Stat Fact Sheets 2009 (Accessed March 10, 2010, at http://seer.cancer.gov/statfacts/html/pancreas.html).

Shi, C. , Hruban, R. and Klein, A. ( 2009) Familial pancreatic cancer. Arch Pathol Lab Med 133: 365-374.

Spratlin, J. , Sangha, R. , Glubrecht, D. , Dabbagh, L. , Young, J. , Dumontet, C. et al. (2004) The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 10: 6956-6961.

Tempero, M. , Plunkett, W. , Ruiz Van Haperen, V. , Hainsworth, J. , Hochster, H. , Lenzi, R. et al. (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21: 3402-3408.

Von Hoff, D. , Ramanathan, R. , Borad, M. , Laheru, D. , Smith, L. , Wood, T. et al. (2009) SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study. J Clin Oncol 27: 2545 [Abstract].